Prevalence, predictors, and impact of low high-density lipoprotein cholesterol on in-hospital outcomes among acute coronary syndrome patients in the middle east

Open Cardiovascular Medicine Journal

Volumn 5, Issue 1, 2011, Pages 203-209

  Al Rasadi, Khalid ^a   Al Zakwani, Ibrahim ^b   Zubaid, Mohammad ^c   Ali, Amr ^d   Bahnacy, Yasser ^d   Sulaiman, Kadhim ^e   Mahmeed, Wael Al ^f   Suwaidi, Jassim Al ^g   Mikhailidis, Dimitri P ^h  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^b SULTAN QABOOS UNIVERSITY   (Oman)

^c KUWAIT UNIVERSITY   (Kuwait)

^d MINISTRY OF HEALTH   (Kuwait)

^e ROYAL HOSPITAL   (Oman)

^f SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^g HAMAD MEDICAL CORPORATION   (Qatar)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Acute coronary syndrome; Gender; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Middle east; Myocardial infarction; Triglycerides

Indexed keywords

BEZAFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BODY MASS; CARDIOGENIC SHOCK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MORTALITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING;

EID: 80053524180     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401105010203     Document Type: Article

References (46)

1. Sacks FM. Expert Group on HDL cholesterol. The role of highdensity lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 15: 139-43.
2. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99: 736-43.
3. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
5. Chapman MJ, Assmann G, Fruchart JC, et al. European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20: 1253-68.
6. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 2008; 94: 706-14.
7. Al-Rasadi K, Sulaiman K, Panduranga P, Al-Zakwani I. Prevalence, characteristics, and in-hospital outcomes of metabolic syndrome among acute coronary syndrome patients from Oman. Angiology 2011; in press
8. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III), Final report. Circulation 2002; 106: 3143-421.
9. Al-Zakwani I, Sulaiman K, Al-Rasadi K. Prevalence of low highdensity lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. Curr Med Res Opin 2011; 27: 879-85.
10. Zubaid M, Rashed WA, Al-Khaja N, et al. Clinical presentation and outcomes of acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Saudi Med J 2008; 29: 251-5.
11. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001; 38: 2114-30.
12. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
13. Alberti KG, Eckel RH, Scott M, et al. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
14. Mabry RM, Reeves MM, Eakin EG, et al. Gender differences in the prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: systematic review. Diabet Med 2010; 27, 593-7.
15. Hadi HAR, Zubaid M, Al Mahmeed W. The prevalence and outcome of excess body weight among middle eastern patients presenting with acute coronary syndrome. Angiology 2010; 61: 456-64.
16. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-50.
17. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular mortality in middle-aged men. JAMA 2002; 288: 2709-16.
18. Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 2005; 96: 3K-13K. Discussion 34K-35K.
19. Shepherd J, Barter P, Carmena R, et al. for the Treating to New Targets Investigators: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-6.
20. Kato M, Dote K, Naganuma T. clinical predictors of culprit plaque rupture assessed on intravascular ultrasound in acute coronary syndrome. Circ J 2010; 74: 1936-42.
21. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21: S5-S9.
22. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med 2007; 357: 1301-10.
23. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low-density lipoprotein cholesterol. J Am Coll Cardiol 2008; 51: 49-55.
24. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010; 153: 800-8.
25. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get with the Guidelines. Am Heart J 2009; 157: 111-7.
26. Roe MT, Ou FS, Alexander KP, et al. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2008; 29: 2480-8.
27. Wolfram M, Brewer HB, Roswitha ZX, et al. Impact of low highdensity lipoproteins on in hospital events and one-year clinical outcomes in patients with non- ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol 2006; 98: 711-7.
28. Pint́o X, Milĺan J, Muñoz A, et al. A very high prevalence of low HDL cholesterol in spanish patients with acute coronary syndromes. Clin Cardiol 2010; 33: 418-23.
29. Arai H, Hiro T, Kimura T, et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome. J Atheroscler Thromb 2010; 17: 1096-107.
30. Correia LC, Rocha MS, Esteves JP. HDL-cholesterol level provides additional prognosis in acute coronary syndromes. Int J Cardiol 2009; 136: 307-14.
31. Olsson AG, Schwarts GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005; 26: 890-6.
32. Zeller M, Steg PG, Ravisy J, et al. for the Observatoire des Infarctus de Côted'Or Survey Working Group: Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005; 165: 1192-8.
33. El-Menyar A, Zubaid M, Rashed W, et al. Comparison of men and women with acute coronary syndrome in six middle eastern countries. Am J Cardiol 2009; 104: 1018-22
34. Cannon CP, Braunwald E, McCabe CH, et al. Intensive vs. moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
35. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-16.
36. SoRelle R. ATP III calls for more intensive low-density lipoprotein lowering in target groups. Circulation 2002; 106: e9068.
37. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA 2003; 290: 2292-300.
38. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.
39. Taylor AJ, Villines TC, Stanek EJ. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361: 2113-22.
40. Genest J, McPherson R, Frohlich J, et al. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009. Can J Cardiol 2009; 25: 567-79.
41. NIH pulls plug on AIM-HIGH trial with niacin MAY 27, 2011 {pipe} Lisa Nainggolan, Available at: http://www.theheart.org/article/1231453.do
42. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and metaregression analysis. BMJ 2009; 338: b92.
43. Fazio S, Linton MF. High-density lipoprotein therapeutics and cardiovascular prevention. J Clin Lipidol 2010; 4: 411-9.
44. Besler C, Heinrich K, Rohrer L et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011; 121: 2693-708.
45. Pfohl M, Schreiber I, Liebich HM, et al. Upregulation of cholesterol synthesis after acute myocardial infarction is cholesterol a positive acute phase reactant? Atherosclerosis 1999; 142: 389-93.
46. Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol 2008; 51: 1440-5.